Page last updated: 2024-08-24

gemcitabine and Dermatoses

gemcitabine has been researched along with Dermatoses in 6 studies

Research

Studies (6)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (16.67)	29.6817
2010's	5 (83.33)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Beck, JT; Bell-McGuinn, K; Eisenberg, P; Emanuelson, R; Hermann, RC; Hudis, CA; Isaacs, C; Kaklamani, V; Keaton, M; Kirshner, JJ; Levine, E; Lokker, NA; Makari-Judson, G; Medgyesy, DC; Qamar, R; Ro, SK; Rugo, HS; Schwartzberg, LS; Starr, A; Stepanski, EJ; Tauer, KW; Wang, W	1
Alousi, AM; Anderlini, P; Champlin, RE; Fanale, MA; Hagemeister, FB; Hosing, CM; Khouri, IF; Ledesma, C; Neelapu, S; Nieto, Y; Oki, Y; Plair, T; Popat, UR; Romaguera, JE; Saliba, RM; Shpall, EJ; Younes, A	1
Brendel, E; Kornacker, M; Kummer, G; Schultheis, B; Strumberg, D; Xia, C; Zeth, M	1
Obeid, KM; Venugopal, AA	1
Guo, Z; Li, J	1

Reviews

1 review(s) available for gemcitabine and Dermatoses

Article	Year
Gemcitabine-associated "pseudocellulitis" and "pseudosepsis": a case report and review of the literature. American journal of therapeutics, 2013, Volume: 20, Issue:1 Topics: Aged; Antimetabolites, Antineoplastic; Cellulitis; Deoxycytidine; Diagnosis, Differential; Edema; Female; Fever; Gemcitabine; Humans; Pancreatic Neoplasms; Sepsis; Skin Diseases; Tachycardia	2013

Trials

2 trial(s) available for gemcitabine and Dermatoses

Article	Year
Sorafenib or placebo with either gemcitabine or capecitabine in patients with HER-2-negative advanced breast cancer that progressed during or after bevacizumab. Clinical cancer research : an official journal of the American Association for Cancer Research, 2013, May-15, Volume: 19, Issue:10 Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Fatigue; Female; Fluorouracil; Gemcitabine; Humans; Kaplan-Meier Estimate; Middle Aged; Niacinamide; Phenylurea Compounds; Receptor, ErbB-2; Skin Diseases; Sorafenib; Stomatitis; Treatment Outcome	2013
Phase IB study of sorafenib in combination with gemcitabine and cisplatin in patients with refractory solid tumors. Cancer chemotherapy and pharmacology, 2012, Volume: 69, Issue:2 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Benzenesulfonates; Cisplatin; Deoxycytidine; Drug Administration Schedule; Drug Resistance, Neoplasm; Gastrointestinal Diseases; Gemcitabine; Hematologic Diseases; Humans; Metabolic Clearance Rate; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Skin Diseases; Sorafenib; Treatment Outcome	2012

Article

Year

Sorafenib or placebo with either gemcitabine or capecitabine in patients with HER-2-negative advanced breast cancer that progressed during or after bevacizumab.

Clinical cancer research : an official journal of the American Association for Cancer Research, 2013, May-15, Volume: 19, Issue:10

Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Fatigue; Female; Fluorouracil; Gemcitabine; Humans; Kaplan-Meier Estimate; Middle Aged; Niacinamide; Phenylurea Compounds; Receptor, ErbB-2; Skin Diseases; Sorafenib; Stomatitis; Treatment Outcome

2013

Phase IB study of sorafenib in combination with gemcitabine and cisplatin in patients with refractory solid tumors.

Cancer chemotherapy and pharmacology, 2012, Volume: 69, Issue:2

Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Benzenesulfonates; Cisplatin; Deoxycytidine; Drug Administration Schedule; Drug Resistance, Neoplasm; Gastrointestinal Diseases; Gemcitabine; Hematologic Diseases; Humans; Metabolic Clearance Rate; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Skin Diseases; Sorafenib; Treatment Outcome

2012

Other Studies

3 other study(ies) available for gemcitabine and Dermatoses

Article	Year
Gemcitabine, Fludarabine, and Melphalan for Reduced-Intensity Conditioning and Allogeneic Stem Cell Transplantation for Relapsed and Refractory Hodgkin Lymphoma. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2016, Volume: 22, Issue:7 Topics: Adult; Brentuximab Vedotin; Deoxycytidine; Female; Gemcitabine; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Immunoconjugates; Lung Diseases; Male; Melphalan; Middle Aged; Nausea; Remission Induction; Salvage Therapy; Skin Diseases; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Young Adult	2016
Gemcitabine: cutaneous, hepatic and vascular disorders. Prescrire international, 2009, Volume: 18, Issue:101 Topics: Antimetabolites, Antineoplastic; Cellulitis; Chemical and Drug Induced Liver Injury; Cytotoxins; Deoxycytidine; Drug Approval; France; Gemcitabine; Humans; Ischemia; Necrosis; Skin Diseases; Stevens-Johnson Syndrome; Vascular Diseases	2009
[Selected arterial infusion chemotherapy combined with target drugs for non-small cell lung cancer with multiple brain metastase]. Zhongguo fei ai za zhi = Chinese journal of lung cancer, 2012, Volume: 15, Issue:5 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Carcinoma, Non-Small-Cell Lung; Crown Ethers; Deoxycytidine; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Gemcitabine; Humans; Infusions, Intra-Arterial; Leukopenia; Lung Neoplasms; Male; Middle Aged; Nimustine; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Skin Diseases; Survival Analysis; Treatment Outcome	2012